2025
Safety and efficacy of the Celt arterial closure device in a femoral first neuroendovascular practice: prospective cohort study
Padmanaban V, Birmingham A, Sujijantarat N, Regenhardt R, Rabinov J, Stapleton C, Patel A. Safety and efficacy of the Celt arterial closure device in a femoral first neuroendovascular practice: prospective cohort study. Journal Of NeuroInterventional Surgery 2025, jnis-2025-024065. PMID: 40846481, DOI: 10.1136/jnis-2025-024065.Peer-Reviewed Original ResearchSingle center prospective studyDual antiplatelet therapyArterial closure devicesGroin hematomaNeuroendovascular proceduresArterial closureRed blood cell transfusionIpsilateral deep vein thrombosisClosure deviceFemoral access proceduresBlood cell transfusionAge of patientsDeep vein thrombosisFemoral artery closureProspective cohort studyAccess site complicationsCell transfusionRetroperitoneal hematomaMinor complicationsAntithrombotic regimensTherapeutic anticoagulationInterventional repairAntiplatelet therapyPatient demographicsVein thrombosisUse and Outcomes of Peripherally Inserted Central Catheters in Hospitalized Infants.
Chegondi M, Ness-Cochinwala M, Schreiber H, Pinto M, Polikoff L, Kothari H, Bloxham J, Kaipa S, Bergman-Sieger A, Mancuso B, Harder T, Korn S, Gillette C, Taillie E, Cholette J, Kerris E, Johnson R, Faustino E. Use and Outcomes of Peripherally Inserted Central Catheters in Hospitalized Infants. Hospital Pediatrics 2025, 15: 748-757. PMID: 40763931, DOI: 10.1542/hpeds.2024-008246.Peer-Reviewed Original ResearchConceptsPeripherally inserted central cathetersCatheter-related thrombosisRandomized clinical trialsMulticenter retrospective cohort studyHospitalized infantsAntiplatelet therapyCentral cathetersElevated mean platelet volumeMean platelet volumeIntensive care unitMichigan Appropriateness GuideMedian agePlatelet volumePediatric guidelinesClinical trialsIntravenous cathetersCare unitInfantsMedical recordsElectronic medical recordsTherapyCatheterAvailability of patientsAntiplateletDaysOutcomes of Patients With Embolic Stroke of Undetermined Source Treated With Antiplatelet Agents or Anticoagulation
Siegler J, Goicoechea E, Penckofer M, Eklund K, Yaghi S, Stretz C, Lineback C, Stamm B, Peter S, D'Souza M, Conyers F, Khasiyev F, Kerrigan D, Lewis S, Ali H, Aboul-Nour H, Sharma R, Nahab F, Glover P, Thompson S, Alshaer Q, Thottempudi N, de Havenon A, Culbertson C, Melkumova E, Chionatos R, Jillella D, Daniel J, Ro J, Frankel M, Dumitrascu O, Brown S, Parikh P, Doolittle C, Yahnke I, Sathya A, Kang J, Kirchhoffer K, Bowman A, Smith M, Brorson J, Asabere A, Shahrivari M, Elangovan C, Sheibani N, Krishnaiah B, Gaudio E, Sloane K, Rothstein A, Alvi M, Annam S, Amankwah C, Kam W, Abburi N, Farooqui M, Rojas-Soto D, Molaie A, Khezri N, Zubair A, Abbasi M, Van Coevering R, Chen L, Nedelcu S, Herpich F, Chahien D, Sehgal S, Liebeskind D, Linares G, Zha A, Sarkar M, Xi R, Nelson A, Abu Qdais A, Al Kasab S, Singh E, Patel V, Aziz Y, Mehndiratta P, DeMarco A, Sharrief A, Cucchiara B, Salehi Omran S, Nguyen T, Dubinski M, Ackerman J, Thon J. Outcomes of Patients With Embolic Stroke of Undetermined Source Treated With Antiplatelet Agents or Anticoagulation. Neurology 2025, 105: e213876. PMID: 40609061, DOI: 10.1212/wnl.0000000000213876.Peer-Reviewed Original ResearchConceptsInverse probability of treatment weightingPotential embolic sourcesBenefits of anticoagulationLeft ventricular injuryEmbolic sourceEmbolic strokeMajor bleedingAntiplatelet therapyVentricular injuryComposite outcomeMedian NIH Stroke Scale scoreCohort studyRecurrent strokePrimary outcomePatients treated with anticoagulantsRetrospective observational cohort studyIschemic strokeTreated with anticoagulationConsecutive adult patientsRisk of recurrenceOutcomes of patientsCox proportional hazards regressionInverse probabilityNIH Stroke Scale scoreProbability of treatment weightingTraumatic Vertebral Artery Injury: Diagnosis, Natural History, and Key Considerations for Management
Teasdale B, Owolo E, Padmanaban V, Elsamadicy A, Amllay A, Shankar G, Krieger P, Regenhardt R, Hebert R, Stapleton C, Rabinov J, Matouk C, Patel A, Sujijantarat N. Traumatic Vertebral Artery Injury: Diagnosis, Natural History, and Key Considerations for Management. Journal Of Clinical Medicine 2025, 14: 3159. PMID: 40364191, PMCID: PMC12072270, DOI: 10.3390/jcm14093159.Peer-Reviewed Original ResearchVertebral artery injuryBlunt cervical spine traumaRisk of vertebral artery injuryNatural historyCervical spine traumaVertebral artery occlusionPotential risk of strokeRisk of strokeComprehensive narrative reviewCo-existing injuriesCervical traumaSpine traumaSpinal cord injuryIntracranial hemorrhageIschemic sequelaeEndovascular managementAntiplatelet therapySurgical interventionRecanalization rateArterial injuryArtery occlusionIncreased riskTherapeutic strategiesDiagnostic approachBony injuriesPost-Transcatheter Aortic Valve Replacement Antithrombotic Treatment in Nonindicated Patients Updated Systematic Review and Network Meta-Analysis
Siami S, Kazemian S, Maleki S, Ebrahimi E, Jodeiri F, Ebrahimzade M, Hajiqasemi M, Ebrahimi S, Mehdizadeh M, Aghaei M, Bastan M, Sabet M, Nazari R, Ebrahimi P, Rana J, Nanna M, Giri J, Kolte D, Biering-Sørensen T, Alkhouli M, Hosseini K. Post-Transcatheter Aortic Valve Replacement Antithrombotic Treatment in Nonindicated Patients Updated Systematic Review and Network Meta-Analysis. JACC Advances 2025, 4: 101719. PMID: 40286375, PMCID: PMC12049831, DOI: 10.1016/j.jacadv.2025.101719.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementDual antiplatelet therapyOral anticoagulantsAntithrombotic regimensNetwork Meta-AnalysisAntiplatelet therapyCardiovascular mortalityMyocardial infarctionRisk of all-cause mortalityChronic oral anticoagulationAortic valve replacementMeta-analysisOptimal antithrombotic strategyIncreased risk of mortalityFrequentist network meta-analysisRisk of cardiovascular mortalityChronic obstructive pulmonary diseaseAll-Cause MortalityRisk of mortalityObstructive pulmonary diseaseBleeding riskValve replacementAntithrombotic treatmentNo significant differenceAntithrombotic strategiesFactors Associated With Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection
Mandel D, Shu L, Chang C, Jack N, Guerrero C, Henninger N, Muppa J, Affan M, Lodhi O, Heldner M, Antonenko K, Seiffge D, Arnold M, Omran S, Crandall R, Lester E, Mena D, Arauz A, Nehme A, Boulanger M, Touzé E, Sousa J, Sargento-Freitas J, Barata V, Castro-Chaves P, Brito M, Khan M, Mallick D, Rothstein A, Khazaal O, Kaufman J, Engelter S, Traenka C, de Sousa D, Soares M, Rosa S, Zhou L, Gandhi P, Field T, Mancini S, Metanis I, Leker R, Pan K, Dantu V, Baumgartner K, Burton T, von Rennenberg R, Nolte C, Choi R, MacDonald J, Shahripour R, Guo X, Ghannam M, Almajali M, Samaniego E, Sanchez S, Rioux B, Zine-Eddine F, Poppe A, Fonseca A, Baptista M, Cruz D, Romoli M, De Marco G, Longoni M, Keser Z, Griffin K, Kuohn L, Frontera J, Amar J, Giles J, Zedde M, Pascarella R, Grisendi I, Nzwalo H, Liebeskind D, Molaie A, Cavalier A, Kam W, Mac Grory B, Al Kasab S, Anadani M, Kicielinski K, Eltatawy A, Chervak L, Rivas R, Aziz Y, Bakradze E, Tran T, Gisbert M, Requena M, Velez F, Garcia J, Muddasani V, de Havenon A, Vishnu V, Yaddanapudi S, Adams L, Browngoehl A, Ranasinghe T, Dunston R, Lynch Z, Penckofer M, Siegler J, Mayer S, Willey J, Zubair A, Cheng Y, Sharma R, Marto J, Ferreira V, Klein P, Nguyen T, Asad S, Sarwat Z, Balabhadra A, Patel S, Secchi T, Martins S, Mantovani G, Kim Y, Krishnaiah B, Elangovan C, Lingam S, Qureshi A, Fridman S, Alvarado-Bolanos A, Khasiyev F, Linares G, Mannino M, Terruso V, Vassilopoulou S, Tentolouris-Piperas V, Marino M, Wall V, Indraswari F, Jamal S, Liu S, Alvi M, Ali F, Sarvath M, Morsi R, Kass-Hout T, Shi F, Zhang J, Sokhi D, Said J, Mongare N, Simpkins A, Gomez R, Sen S, Ghani M, Elnazeir M, Xiao H, Kala N, Khan F, Stretz C, Mohammadzadeh N, Goldstein E, Furie K, Yaghi S. Factors Associated With Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection. Stroke 2025, 56: 1413-1421. PMID: 40143807, DOI: 10.1161/strokeaha.124.048215.Peer-Reviewed Original ResearchConceptsCervical artery dissectionCox regressionOcclusive dissectionIschemic strokeArtery dissectionAssociated with subsequent stroke riskDiagnosis of cervical artery dissectionFactors associated with increased riskAssociated with increased risk of ischemic strokeStroke riskTreated with anticoagulationAssociated with increased riskOptimal treatment strategyHistory of ischemic strokeRetrospective observational studyRisk of ischemic strokeBenefits of anticoagulationIschemic stroke riskFactors associated with stroke recurrenceHigh-risk individualsIdentified risk factorsPost Hoc AnalysisCAD subgroupAntiplatelet therapyInitial diagnosisCarotid artery stenting with open vs closed stent cell configurations in the CREST-2 Registry
Lal B, Roubin G, Meschia J, Jones M, Heck D, Sternbergh W, Aronow H, Mena-Hurtado C, Howard G, Mayorga-Carlin M, Sorkin J, Brott T. Carotid artery stenting with open vs closed stent cell configurations in the CREST-2 Registry. Journal Of Vascular Surgery 2025, 82: 127-135.e1. PMID: 40024381, DOI: 10.1016/j.jvs.2025.02.025.Peer-Reviewed Original ResearchCarotid artery stentingOpen-cell stentClosed-cell stentsFood and Drug Administration-approved deviceArtery stentingEmbolic protectionComparison of clinical outcomesStandardized procedure protocolsSymptomatic patientsPeri-proceduralAntiplatelet therapyPatient selectionClinical outcomesInstitutional experiencePatient characteristicsProcedural detailsCREST-2Lesion characteristicsLesion selectionHigh riskStentVascular anatomyPatient preferencesPatientsProcedure protocolEfficacy and safety of intravenous alteplase for unknown onset stroke on prior antiplatelet therapy: Post hoc analysis of the EOS individual participant data
Shiomi Y, Miwa K, Jensen M, Inoue M, Yoshimura S, Kamogawa N, Fukuda-Doi M, Ma H, Ringleb P, Wu O, Schwamm L, Davis S, Donnan G, Gerloff C, Nakahara J, Toyoda K, Thomalla G, Koga M. Efficacy and safety of intravenous alteplase for unknown onset stroke on prior antiplatelet therapy: Post hoc analysis of the EOS individual participant data. International Journal Of Stroke 2025, 20: 679-686. PMID: 39921231, PMCID: PMC12182598, DOI: 10.1177/17474930251322034.Peer-Reviewed Original ResearchSymptomatic intracranial hemorrhagePrevalence of vascular risk factorsIntravenous alteplaseSafety of intravenous alteplaseIndividual participant dataEffect of intravenous alteplaseControl groupVascular risk factorsRandomized Controlled TrialsRisk of symptomatic intracranial hemorrhageDays post-strokeRate of symptomatic intracranial hemorrhagePost-strokeAlteplase groupAntiplatelet therapy groupParticipant dataSafety outcomesAntiplatelet therapyStroke thrombolysisAntiplatelet therapy patientsControlled TrialsBaseline dataModified Rankin Scale scoreFavorable outcomeRisk factorsSex Differences in the Safety and Efficacy of Different Durations of DAPT After PCI
Park D, Mahajan S, Fishman E, Ambrosini A, Acero L, Hu J, Campbell G, Babapour G, Kelsey M, Douglas P, Gupta A, Frampton J, Nanna M. Sex Differences in the Safety and Efficacy of Different Durations of DAPT After PCI. JACC Advances 2025, 4: 101543. PMID: 39886301, PMCID: PMC11780104, DOI: 10.1016/j.jacadv.2024.101543.Peer-Reviewed Original ResearchMonths of DAPTDuration of dual antiplatelet therapyNet adverse clinical eventsDuration of DAPTRandomized Controlled TrialsPercutaneous coronary interventionShorter duration of dual antiplatelet therapyRisk of bleedingBleeding riskLow risk of bleedingSex-based differencesAssociated with lower riskAdverse clinical eventsDual antiplatelet therapyAdverse cardiovascular eventsNetwork Meta-AnalysisWeb of Science databasesAntiplatelet therapyClinical impactCardiovascular eventsClinical eventsSystematic reviewSignificant sex-based differencesControlled TrialsCoronary intervention
2024
Demographic diversity in platelet function and response to antiplatelet therapy
Jain K, Tyagi T, Gu S, Faustino E, Hwa J. Demographic diversity in platelet function and response to antiplatelet therapy. Trends In Pharmacological Sciences 2024, 46: 78-93. PMID: 39672782, PMCID: PMC11710996, DOI: 10.1016/j.tips.2024.11.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsResponse to antiplatelet therapyCardiovascular diseaseAntiplatelet therapyPlatelet biologyPathological platelet activationCardiovascular disease riskNon-genetic factorsPopulation-based differencesAntiplatelet strategiesPlatelet functionCardiovascular outcomesDiverse rolesPlatelet activationTherapeutic approachesTherapyPlateletBiologyRacial and Ethnic Disparities in the Use and Outcomes With WATCHMAN FLX: A SURPASS Analysis of the NCDR Left Atrial Appendage Occlusion Registry
Alli O, Garg J, Boursiquot B, Kapadia S, Yeh R, Price M, Piccini J, Nair D, Hsu J, Gibson D, Allocco D, Christen T, Sutton B, Freeman J. Racial and Ethnic Disparities in the Use and Outcomes With WATCHMAN FLX: A SURPASS Analysis of the NCDR Left Atrial Appendage Occlusion Registry. Journal Of The American Heart Association 2024, 13: e036406. PMID: 39575715, PMCID: PMC11681556, DOI: 10.1161/jaha.124.036406.Peer-Reviewed Original ResearchLeft atrial appendage occlusionWatchman FLX implantationBlack patientsHispanic patientsOral anticoagulantsProcedural successRates of 1-year deathWhite patientsAlternative to oral anticoagulationRate of procedural successEthnic minority groupsEthnic minority individualsRate of deathSignificant bleedingWatchman FLXMinority individualsAppendage occlusionAntiplatelet therapyBaseline characteristicsAtrial fibrillationAnalyses assessed differencesMinority groupsPatientsStroke preventionBleedingAnticoagulation Alone vs Anticoagulation Plus Aspirin or DAPT Following Left Atrial Appendage Occlusion
Reinhardt S, Gibson D, Hsu J, Kapadia S, Yeh R, Price M, Piccini J, Nair D, Christen T, Allocco D, Freeman J. Anticoagulation Alone vs Anticoagulation Plus Aspirin or DAPT Following Left Atrial Appendage Occlusion. Journal Of The American College Of Cardiology 2024, 84: 889-900. PMID: 39197978, DOI: 10.1016/j.jacc.2024.05.067.Peer-Reviewed Original ResearchConceptsLeft atrial appendage occlusionRate of adverse eventsAdverse eventsLAA closure deviceAppendage occlusionAntithrombotic strategiesP2Y<sub>12</sub> inhibitorsDays of follow-upMultivariable Cox proportional hazards regressionClosure deviceRisk of adverse eventsCox proportional hazards regressionWatchman FLX deviceDual antiplatelet therapyDevice-related thrombusProportional hazards regressionStroke/transient ischemic attackAntithrombotic regimensFLX deviceAntiplatelet therapyDOACsGroup patientsFollow-upMultivariate analysisHazards regressionEarly thrombus formation is required for eccentric and heterogeneous neointimal hyperplasia under disturbed flow
Bai H, Li Z, Zhang W, Thaxton C, Ohashi Y, Gonzalez L, Kano M, Yatsula B, Hwa J, Dardik A. Early thrombus formation is required for eccentric and heterogeneous neointimal hyperplasia under disturbed flow. Journal Of Thrombosis And Haemostasis 2024, 22: 3614-3628. PMID: 39173878, PMCID: PMC11608155, DOI: 10.1016/j.jtha.2024.07.028.Peer-Reviewed Original ResearchEndothelial cell lossArteriovenous fistulaSmooth muscle cellsNeointimal hyperplasiaHeterogeneous neointimaCell lossThrombus formationMT/mG reporter miceHuman arteriovenous fistulaeInhibit neointimal hyperplasiaEarly thrombus formationAntiplatelet therapyC57BL/6 miceReporter miceAVF failureWistar ratsVenous systemJuxta-anastomotic areaMuscle cellsAnimal modelsVenous outflowEarly thrombusEndothelial cellsArterial inflowThrombusMilvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome
Tantry U, Raghavakurup L, Becker R, Singh S, Bliden K, Gurbel P. Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome. Expert Opinion On Pharmacotherapy 2024, 25: 1271-1280. PMID: 39072402, DOI: 10.1080/14656566.2024.2385062.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeCoronary syndromeElevated risk of bleedingPathological thrombosisTreatment of acute coronary syndromesClinical thrombotic eventsPhysiological hemostasisRisk of bleedingPrevention of thrombosisFXIa inhibitorsBleeding riskReceptor blockersThrombotic eventsAntiplatelet therapyPlatelet antagonistsAntithrombotic efficacyFXIa inhibitionThrombosisExperimental thrombosisPatientsElevated riskLiterature searchAnticoagulationLarge-scale studiesFXIaContemporary Prestroke Dual Antiplatelet Use and Symptomatic Intracerebral Hemorrhage Risk After Thrombolysis
Peng T, Schwamm L, Fonarow G, Hassan A, Hill M, Messé S, Coronado F, Falcone G, Sharma R. Contemporary Prestroke Dual Antiplatelet Use and Symptomatic Intracerebral Hemorrhage Risk After Thrombolysis. JAMA Neurology 2024, 81: 722-731. PMID: 38767894, PMCID: PMC11106713, DOI: 10.1001/jamaneurol.2024.1312.Peer-Reviewed Original ResearchRisk of symptomatic intracerebral hemorrhageSymptomatic intracerebral hemorrhageTreated with IV-tPAAcute ischemic strokeIV-tPAAmerican Heart Association and American Stroke AssociationAssociated with lower oddsIschemic strokeDual antiplatelet therapyAssociated with increased riskPropensity score subclassificationAmerican Stroke AssociationIntracerebral hemorrhage riskGWTG-StrokeSymptomatic intracerebral hemorrhage riskGuidelines-StrokeDischarge modified Rankin Scale scoreIn-Hospital DeathStroke AssociationLower oddsRate of symptomatic intracerebral hemorrhageAntiplatelet therapyCohort studyAssociated with symptomatic intracerebral hemorrhagePrestrokeMulticenter early United States feasibility study and periprocedural safety of LVIS EVO for the treatment of unruptured intracranial aneurysms
Kayan Y, Almandoz J, Copelan A, Matouk C, Chaudry M, Altschul D, Essibayi M, Goren O, Yim B, Tsappidi S, Zhang Y, Hui F, Samaniego E, Gudino A, Siddiqui A, Jaikumar V, Puri A, Kühn A, Singh J, Ringer A, Hanel R, De Toledo O, Dabus G, Gooch M, Sizdahkhani S, Field N, Paul A. Multicenter early United States feasibility study and periprocedural safety of LVIS EVO for the treatment of unruptured intracranial aneurysms. Journal Of NeuroInterventional Surgery 2024, 17: jnis-2024-021900. PMID: 38906689, DOI: 10.1136/jnis-2024-021900.Peer-Reviewed Original ResearchConceptsLow-profile visualized intraluminal supportIntracranial aneurysmsHemorrhagic complicationsTreatment of unruptured intracranial aneurysmsComplete neck coverageAverage aneurysm sizeInstitutional review board approvalClass I occlusionReview board approvalAnterior communicating arteryTreatment of intracranial aneurysmsMiddle cerebral artery bifurcationUnruptured intracranial aneurysmsSelf-expanding stentsCerebral artery bifurcationLength of stayParent vessel sizePatient agePeriprocedural complicationsPeriprocedural safetyAneurysm locationAneurysm sizeAntiplatelet therapyBoard approvalIntraluminal supportAnticoagulation Versus Antiplatelets in Spontaneous Cervical Artery Dissection: A Systematic Review and Meta-Analysis
Yaghi S, Shu L, Fletcher L, Fayad F, Shah A, Herning A, Isho N, Mansour P, Joudi K, Zaidat B, Mahmoud N, Khalek F, Xiao H, Goldstein E, Ghannam M, Siegler J, Omran S, Bakradze E, Nguyen T, Keser Z, Khan M, Shahripour R, de Havenon A, Henninger N, Heldner M, Field T, Aziz Y, Mistry E, Furie K, Engelter S, Markus H. Anticoagulation Versus Antiplatelets in Spontaneous Cervical Artery Dissection: A Systematic Review and Meta-Analysis. Stroke 2024, 55: 1776-1786. PMID: 38847098, DOI: 10.1161/strokeaha.124.047310.Peer-Reviewed Original ResearchConceptsCervical artery dissectionSystematic reviewArtery dissectionMeta-analysisBleeding riskIschemic stroke riskAntiplatelet therapyRandomized trialsSpontaneous cervical artery dissectionRisk of deathIschemic strokeCombination of keywordsTreated with antiplateletSafety of dual antiplatelet therapyReducing ischemic strokeSymptomatic intracranial hemorrhageOptimal antithrombotic strategyMajor traumaDual antiplatelet therapyIndividualized therapeutic approachStudy of patientsInclusion criteriaRandomized clinical trialsMeta-analysesEffect sizeTracheostomy in Patients with Acute Myocardial Infarction and Respiratory Failure
Grammatico M, Banna S, Shahu A, Gastanadui M, Jimenez J, Heck C, Arias-Olson A, Thomas A, Ali T, Miller P. Tracheostomy in Patients with Acute Myocardial Infarction and Respiratory Failure. Journal Of Intensive Care Medicine 2024, 39: 1131-1137. PMID: 38715423, DOI: 10.1177/08850666241253202.Peer-Reviewed Original ResearchDays of tracheostomyInvasive mechanical ventilationIn-Hospital MortalityAcute myocardial infarctionTiming of tracheostomyRespiratory failureAntiplatelet regimensMyocardial infarctionAssociated with lower in-hospital mortalityIncidence of tracheostomyLower In-Hospital MortalityProportion of patientsIncidence of patientsDiagnosis of acute myocardial infarctionDAPT interruptionTracheostomy complicationsBlood transfusionOpen tracheostomyAntiplatelet therapyMechanical ventilationMultivariable adjustmentDAPT usePrimary diagnosis of acute myocardial infarctionClinical data baseTracheostomyClinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach
Regan C, Scierka L, Dardik A, Tonnessen B, Chaar C, Ionescu C, Aboian E, Cardella J, Nassiri N, Guzman R, Attaran R, Nagpal S, Shah S, Smolderen K, Mena-Hurtado C. Clinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach. Vascular 2024, 33: 466-471. PMID: 38669051, DOI: 10.1177/17085381241246318.Peer-Reviewed Original ResearchDual antiplatelet therapyPeripheral arterial diseaseCYP2C19 testingCYP2C19 mutationsHeterogeneity of treatment effectsPeripheral vascular interventionsConsensus statementKnowledge questionsAntiplatelet therapyGenetic testingVascular surgeryAcademic health systemBarriers to implementationInterquartile rangeCYP2C19 genotype testingVascular diseaseInterventional cardiologyModified Delphi MethodPatient's metabolic statusManagement of patientsCritical limb ischemiaPerceived BarriersPeripheral vascular diseaseArterial vascular diseaseClinician perspectivesThe Impact of Preprocedural Platelet Function Testing on Periprocedural Complication Rates Associated With Pipeline Flow Diversion: An International Multicenter Study
Vranic J, Dmytriw A, Berglar I, Alotaibi N, Cancelliere N, Stapleton C, Rabinov J, Harker P, Gupta R, Bernstock J, Koch M, Raymond S, Mascitelli J, Patterson T, Seinfeld J, White A, Case D, Roark C, Gandhi C, Al-Mufti F, Cooper J, Matouk C, Sujijantarat N, Devia D, Ocampo-Navia M, Villamizar-Torres D, Puentes J, Salem M, Baig A, Namaani K, Kühn A, Pukenas B, Jankowitz B, Burkhardt J, Siddiqui A, Jabbour P, Singh J, Puri A, Regenhardt R, Pereira V, Patel A. The Impact of Preprocedural Platelet Function Testing on Periprocedural Complication Rates Associated With Pipeline Flow Diversion: An International Multicenter Study. Neurosurgery 2024, 95: 179-185. PMID: 38634693, DOI: 10.1227/neu.0000000000002956.Peer-Reviewed Original ResearchPlatelet function testsPipeline Embolization DeviceDual antiplatelet therapyGroup patientsIntracranial complicationsDAPT regimenThromboembolic complicationsPED treatment of intracranial aneurysmsResults of platelet function testingPipeline Embolization Device embolizationPipeline Embolization Device treatmentFunction testsIntracranial aneurysmsPipeline flow diversionPermanent neurological disabilityInternational multicenter studyFlow diversionTreatment of intracranial aneurysmsUnruptured intracranial aneurysmsWilcoxon rank-sumClopidogrel nonrespondersComplication rateMulticenter studyAntiplatelet therapyFisher's exact
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply